[ad_1]
Regeneron Pharmaceuticals (REGN) reported strong first-quarter 2026 results on April 29, 2026, with total revenues rising 19% to $3.6 billion and non-GAAP earnings per diluted share climbing 15% to $9.47 — topping analyst expectations by approximately $0.40. Yet the stock fell more than 7% on Wednesday. The disconnect between the headline beat and the market reaction reflects a familiar tension in Regeneron’s story: Dupixent is delivering extraordinary growth, but the EYLEA franchise continues its structural decline, and investors are pricing in how long the legacy anchor will suppress the blended growth rate.
The quarter also brought a wave of regulatory milestones and a new $3 billion buyback authorization — underscoring management’s view that the pipeline and balance sheet are both in a position of strength.
Q1 2026 Headline Numbers: Revenue Beat, GAAP Versus Non-GAAP Divergence
For the quarter ended March 31, 2026, Regeneron reported total revenues of $3,605 million, up 19% from $3,029 million in Q1 2025. The growth rate exceeded the consensus analyst forecast of approximately $3.48 billion.
Non-GAAP net income per diluted share was $9.47, up 15% from $8.22 in the prior-year quarter, beating analyst estimates of approximately $9.07. The figure includes a $0.80 negative impact from in-process research and development charges.
GAAP net income was $727 million, a 10% decline from $809 million in Q1 2025. GAAP EPS of $6.75 was down 7% from $7.27. The GAAP decline reflects a higher $0.82 IPR&D charge in the current quarter versus the prior-year period, not an operating deterioration.
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Total revenues | $3,605M | $3,029M | +19% |
| GAAP net income | $727M | $809M | -10% |
| GAAP EPS (diluted) | $6.75 | $7.27 | -7% |
| Non-GAAP net income | $1,040M | $928M | +12% |
| Non-GAAP EPS (diluted) | $9.47 | $8.22 | +15% |
Dupixent: The Growth Engine Behind the Results
Dupixent (dupilumab) remained the dominant force in Regeneron’s quarterly performance. Global net sales of Dupixent — recorded by Sanofi under the collaboration agreement — were $4.9 billion in Q1 2026, up 33% year-over-year. Regeneron records its share of the collaboration economics as revenue rather than Dupixent’s gross sales line directly, but the 33% growth rate in the underlying franchise is what flows through to Regeneron’s revenue and profitability.
The expansion of Dupixent’s label continued at a rapid pace. During Q1 2026, the FDA approved Dupixent for chronic spontaneous urticaria (CSU) in young children, making it available for a younger pediatric population. The FDA also approved Dupixent as the first and only medicine for allergic fungal rhinosinusitis (AFRS), a rare but debilitating fungal infection affecting the sinuses. The European Commission separately approved Dupixent for CSU across age groups.
These regulatory wins matter because Dupixent’s revenue trajectory depends not just on existing indications growing into market share but on new indications opening new patient populations. With nearly 50 product candidates in clinical development, Regeneron is investing aggressively to extend the Dupixent platform while building out its next tier of growth drivers.
EYLEA Franchise in Transition: HD Surges While Legacy Declines
The EYLEA franchise tells a split story. EYLEA HD (aflibercept 8 mg), the higher-dose, extended-dosing formulation, posted U.S. net sales of $468 million in Q1 2026, up 52% year-over-year. That growth reflects both increased market adoption and a significant new label expansion: EYLEA HD was approved by the FDA during Q1 2026 for up to 5-month dosing intervals for wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). Extended dosing is a meaningful clinical differentiator for patients who previously required injections every 1–2 months.
However, combined U.S. net sales of EYLEA HD and legacy EYLEA totaled $941 million in Q1 2026, a 10% decline from the prior year. The legacy EYLEA franchise is losing volume as patients and physicians shift to EYLEA HD and as competition from biosimilar aflibercept products increases. The net result is that the high growth in EYLEA HD is not yet large enough to offset the volume erosion in legacy EYLEA.
This franchise transition is a known, expected dynamic — management is not surprised by it. But investors watching the blended EYLEA line will need to see EYLEA HD’s volume eventually overcome legacy attrition. At 52% growth, EYLEA HD is closing that gap, but Q1 numbers confirm it has not yet crossed it.
Capital Allocation and U.S. Drug Pricing: The Policy and Buyback Dimension
Regeneron’s board authorized a new $3 billion share repurchase program during Q1 2026. The authorization follows the company’s track record of returning capital to shareholders and comes as the stock has traded below peak levels, suggesting the board sees the current valuation as an opportunity.
The quarter also brought a notable policy development. Regeneron announced it entered into an agreement with the U.S. government “aimed at making progress toward lowering drug prices for American patients by promoting more balanced pricing with other wealthy nations.” CEO Leonard Schleifer described this as consistent with the company’s long-held position on international reference pricing.
Separately, the FDA approved Otarmeni (lunsotogene parvec) as the first-ever gene therapy for genetic hearing loss — a significant scientific milestone. Regeneron announced it will provide Otarmeni at no cost to eligible patients in the United States, an unusual access strategy that reflects both the rarity of the condition and the company’s stated commitment to patient access.
Key Signals for Investors
- Dupixent’s 33% global sales growth and four new FDA approvals in Q1 2026 demonstrate that the platform continues to expand its addressable patient population; how much of that growth converts to Regeneron’s collaboration revenue in future quarters is the primary profitability driver.
- The 10% decline in the combined EYLEA franchise is a key watch point: EYLEA HD’s 52% growth needs to sustain or accelerate to fully offset legacy erosion, which will likely take several more quarters.
- The GAAP EPS decline of 7% versus non-GAAP EPS growth of 15% reflects IPR&D charges and not operating deterioration; investors should focus on non-GAAP EPS trajectory as the better reflection of ongoing business performance.
- The new $3 billion buyback authorization signals management conviction in the stock at current levels following the post-results share price decline.
- The U.S. drug pricing agreement and Otarmeni free-access policy introduce policy and reimbursement risk as watchpoints, particularly if pricing agreements evolve to include Dupixent or the broader portfolio.
[ad_2]
Source link